Back to top

Analyst Blog

Johnson & Johnson’s (JNJ - Analyst Report) shares were up slightly following the company’s acquisition of GlaxoSmithKline’s (GSK - Analyst Report) hepatitis C virus (HCV) pipeline candidate, GSK2336805. While Johnson & Johnson’s share price edged up 0.4%, Glaxo’s shares were down 0.5% since the product acquisition was announced.

Janssen Pharmaceuticals, Inc., a part of Johnson & Johnson’s Janssen Pharmaceutical Companies, said that it has acquired all rights to develop and commercialize GSK2336805, including in combination with other drugs. Financial terms of the agreement were not available.

GSK2336805 is an NS5a replication complex inhibitor being developed for the treatment of chronic HCV. Janssen will move the candidate into phase II studies in interferon-free combinations with its protease inhibitor simeprevir (TMC435) and its non-nucleoside polymerase inhibitor, TMC647055, for the treatment of chronic HCV in adult patients with compensated liver disease.

This deal is in line with Johnson & Johnson’s efforts to expand its HCV pipeline. Johnson & Johnson currently has an approved HCV product in the form of Incivo. However, the company is working on bringing new investigational interferon-free treatment combinations to market.

Johnson & Johnson has HCV-focused collaborations with several companies. Simeprevir, which is currently under regulatory review in the U.S. Canada and EU, is being developed in collaboration with Medivir AB. It gained approval in Japan in September. Johnson & Johnson is also evaluating simeprevir in collaboration with companies like Gilead (GILD - Analyst Report) and Bristol-Myers Squibb (BMY - Analyst Report) among others.

Johnson & Johnson currently carries a Zacks Rank #3 (Hold). While we expect the company to continue facing headwinds in the form of pricing pressure and manufacturing issues, we believe the diversified business model, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations.

Glaxo currently looks well-positioned with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SYNAPTICS I… SYNA 78.11 +8.14%
GREEN PLAIN… GPRE 39.41 +5.12%
PILGRIM'S P… PPC 28.82 +3.08%
SKYWORKS SO… SWKS 52.07 +2.58%
CLAYTON WIL… CWEI 109.08 +2.51%